RecruitingPhase 2
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Glaukos Corporation · NCT07400952
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–55 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- December 23, 2025
- Record last updated
- February 10, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Being studied: GLK-221 Ophthalmic Solution; Placebo Ophthalmic Solution
Conditions: Keratoconus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Be ≥ 18 and ≤ 55 years of age
- Diagnosis of keratoconus in the study eye
Exclusion Criteria
- Pregnant, lactating or planning a pregnancy
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
Recruiting US locations
Glaukos Clinical Study Site
Westerville, OH 43082
Site contact: Study Manager · 949-739-8749
Study contacts (from the official record)
- Study Manager · 949-739-8749 · ClinicalResearch@Glaukos.com